SCHEMBL9922175

SCHEMBL9922175

O=C(Nc1ccc(N2C(=O)Cc3ccc(S)cc3C2=O)c(F)c1)NS(=O)(=O)c1cccs1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 8/20 0.38
MEN1 O00255 7/20 0.38
LMNA P02545 3/20 0.38
ALDH1A1 P00352 2/20 0.38
RORC P51449 1/20 0.37
MAPT P10636 4/20 0.36
HPGD P15428 1/20 0.36
PTGER3 P43115 2/20 0.35
HTT P42858 2/20 0.35
MAPK1 P28482 1/20 0.35
NPC1 O15118 1/20 0.35
RAB9A P51151 1/20 0.35
POLB P06746 1/20 0.35
GRM1 Q13255 3/20 0.34
TSHR P16473 1/20 0.34
GRM4 Q14833 1/20 0.34
PKM P14618 1/20 0.33
TP53 P04637 1/20 0.33
APOB P04114 1/20 0.33
MTTP P55157 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9922383 0.92 KMT2A (0.41) KMT2AMEN1LMNAALDH1A1RORC
SCHEMBL9922958 0.91 PTGER3 (0.42) KMT2AMEN1LMNAALDH1A1RORC
SCHEMBL14228358 0.91 KMT2A (0.39) KMT2AMEN1LMNAALDH1A1RORC
SCHEMBL13638607 0.90 MEN1 (0.42) KMT2AMEN1LMNAALDH1A1RORC
SCHEMBL9922366 0.90 KMT2A (0.38) KMT2AMEN1LMNAALDH1A1RORC
SCHEMBL9922950 0.90 KMT2A (0.43) KMT2AMEN1LMNAALDH1A1RORC
SCHEMBL9922388 0.89 CA2 (0.42) KMT2AMEN1LMNAALDH1A1RORC
SCHEMBL12177244 0.89 MEN1 (0.39) KMT2AMEN1LMNAALDH1A1RORC
SCHEMBL9922398 0.89 MEN1 (0.40) KMT2AMEN1LMNAALDH1A1RORC
SCHEMBL12161564 0.88 PTGER1 (0.39) KMT2AMEN1LMNAALDH1A1RORC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120149688-A1 PLATELET ADP RECEPTOR INHIBITORS PORTOLA PHARMACEUTICALS, INC. (US) 2012-06-14 US disclosed
US-8067428-B2 Platelet ADP receptor inhibitors PORTOLA PHARMACEUTICALS, INC. (US) 2011-11-29 US disclosed
US-20100234350-A1 PLATELET ADP RECEPTOR INHIBITORS PORTOLA PHARMACEUTICALS, INC. (US) 2010-09-16 US disclosed
US-7622474-B2 Asulfonyl(urea, thiourea, guanidine, cyanoguanidine) compounds; cardiovascular disorders; thrombosis PORTOLA PHARMACEUTICALS, INC. (US) 2009-11-24 US disclosed
US-7358257-B2 sulfonylurea derivatives, sulfonylthiourea derivatives, sulfonylguanidine derivatives, sulfonylcyanoguanidine derivatives, thioacylsulfonamide derivatives, and acylsulfonamide derivatives; effective for prevention and treatment of cardiovascular diseases, antithrombotic agents PORTOLA PHARMACEUTICALS, INC. (US) 2008-04-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100234350-A1 PLATELET ADP RECEPTOR INHIBITORS TBXA2R, GP6, P2RY6 KMT2A 3009/4885MEN1 4498/4885LMNA 3576/4885
US-20120149688-A1 PLATELET ADP RECEPTOR INHIBITORS TBXA2R, GP6, P2RY6 KMT2A 3023/4885MEN1 4499/4885LMNA 3603/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.